We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.9B
1-Year Est. Return 121.13%
This Fund
S&P 500
This Quarter Est. Return
+63.92%
1 Year Est. Return
+121.13%
3 Year Est. Return
+281.43%
5 Year Est. Return
+350.91%
10 Year Est. Return
–
AUM
$1.45B
AUM Growth
+$364M
Cap. Flow
+$152M
Cap. Flow %
10.45%
Top 10 Hldgs %
51.41%
Holding
99
New
31
Increased
26
Reduced
24
Closed
13

Top Buys

Rank Stock Value
1
UTHR icon
United Therapeutics
UTHR
+$65.2M
2
ABVX
Abivax
ABVX
+$26.1M
3
QURE icon
uniQure
QURE
+$15.9M
4
DHR icon
Danaher
DHR
+$15.1M
5
PODD icon
Insulet
PODD
+$14.3M

Top Sells

Rank Stock Value
1
NTRA icon
Natera
NTRA
+$43.8M
2
INSP icon
Inspire Medical Systems
INSP
+$21.3M
3
IQV icon
IQVIA
IQV
+$15.4M
4
PTGX icon
Protagonist Therapeutics
PTGX
+$15.3M
5
MIRM icon
Mirum Pharmaceuticals
MIRM
+$11.6M

Sector Composition

Rank Sector Weight
1 Healthcare 89.94%
2 Financials 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRUS
51
DELISTED
Merus
MRUS
$4.52M 0.31%
48,054
-82,870
-63% -$5.4M
ALEC icon
52
Alector
ALEC
$164M
$4.41M 0.3%
1,488,725
-497,347
-25% -$1.1M
HUM icon
53
Humana
HUM
$46.7B
$4.33M 0.3%
16,652
-26,968
-62% -$7.09M
RAPP
54
Rapport Therapeutics
RAPP
$1.95B
$4.26M 0.29%
+143,565
New +$2.56M
TYRA icon
55
Tyra Biosciences
TYRA
$1.82B
$3.82M 0.26%
+272,706
New +$3.11M
MIRM icon
56
Mirum Pharmaceuticals
MIRM
$6.89B
$3.62M 0.25%
49,314
-182,861
-79% -$11.6M
ZBIO
57
Zenas BioPharma
ZBIO
$1.92B
$3.52M 0.24%
158,742
-166,737
-51% -$2.71M
ACAD icon
58
Acadia Pharmaceuticals
ACAD
$4.25B
$3.5M 0.24%
+164,237
New +$3.88M
BVS icon
59
Bioventus
BVS
$799M
$2.9M 0.2%
+433,933
New +$3.01M
NKTR icon
60
Nektar Therapeutics
NKTR
$2.39B
$2.84M 0.2%
49,890
-65,110
-57% -$2.16M
AMRN
61
Amarin Corp
AMRN
$284M
$2.74M 0.19%
167,276
– –
RLAY icon
62
Relay Therapeutics
RLAY
$4.02B
$2.5M 0.17%
479,056
-54,353
-10% -$207K
GOSS icon
63
Gossamer Bio
GOSS
$66.5M
$2.43M 0.17%
925,233
-770,529
-45% -$1.7M
KURA icon
64
Kura Oncology
KURA
$922M
$2.33M 0.16%
+263,628
New +$1.88M
IFRX icon
65
InflaRx
IFRX
$256M
$2.32M 0.16%
1,730,635
+90,205
+5% +$95.8K
IVVD icon
66
Invivyd
IVVD
$180M
$2.25M 0.16%
+2,047,265
New +$1.82M
AVR
67
Anteris Technologies
AVR
$791M
$2.25M 0.16%
+500,000
New +$1.96M
NVAX icon
68
Novavax
NVAX
$1.23B
$2.11M 0.15%
+243,184
New +$1.89M
ARQT icon
69
Arcutis Biotherapeutics
ARQT
$3.42B
$2.1M 0.14%
+111,466
New +$1.76M
STRO icon
70
Sutro Biopharma
STRO
$379M
$1.99M 0.14%
229,131
-95
-0% -$808
FTRE icon
71
Fortrea Holdings
FTRE
$1.85B
$1.85M 0.13%
219,384
– –
MOH icon
72
Molina Healthcare
MOH
$10.3B
$1.81M 0.12%
9,470
-11,130
-54% -$2.05M
CTNM
73
Contineum Therapeutics
CTNM
$526M
$1.58M 0.11%
+134,619
New +$1.09M
BCYC
74
Bicycle Therapeutics
BCYC
$270M
$1.5M 0.1%
194,440
-17,029
-8% -$129K
PLRX icon
75
Pliant Therapeutics
PLRX
$67.5M
$1.22M 0.08%
+824,594
New +$1.26M
1 2
3
4

Similar funds

DCP
Distillate Capital Partners Chicago, Illinois $1.9B AUM 2.22% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $1.89B AUM 14.55% 1-Year Est. Return
OPCM
Osborne Partners Capital Management San Francisco, California $1.89B AUM 16.21% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return
RCA
Resonant Capital Advisors Madison, Wisconsin $1.9B AUM 14.38% 1-Year Est. Return
IAN
Integrated Advisors Network Dallas, Texas $1.91B AUM 24.91% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
TF
Trek Financial Scottsdale, Arizona $1.88B AUM 41.21% 1-Year Est. Return

Eversept Partners's Q3 2025 Portfolio in Review

As of Q3 2025, Eversept Partners held 99 positions worth $1.45B, up 33% from $1.09B the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Eversept Partners deployed $152M of net new capital in Q3 2025, opening 31 new positions and adding to 26 existing holdings. Its largest new stake was Abivax: 426,499 shares worth $36.2M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 91% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Natera, an estimated $43.8M trimmed.

  • Eversept Partners's largest Q3 2025 buy was Abivax: 426,499 shares worth $36.2M.
  • Eversept Partners added most to United Therapeutics in Q3 2025, an estimated $65.2M increase.
  • Eversept Partners's biggest Q3 2025 reduction was Natera, cutting an estimated $43.8M.
  • Eversept Partners fully exited Inspire Medical Systems in Q3 2025, selling an estimated $21.3M.
  • Eversept Partners's ten largest holdings make up 51% of its $1.45B portfolio in Q3 2025.
  • Eversept Partners opened 31 new positions and closed 13 in Q3 2025.
  • Eversept Partners's portfolio value rose 33% quarter-over-quarter to $1.45B.

Based on Eversept Partners's 13F filing for Q3 2025, filed 14 Nov 2025.